702. CAR-T Cell Therapies: Basic and Translational: Poster I

Targeting of tumor antigen CD38 and stress antigens MICA B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma

Targeting TP53 promotes anti leukemia immunity and enhances CD70 CAR T efficacy in AML by transcriptionally upregulating CD70

Precision targeting of the malignant clone in B cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3 23 B cell receptor

SPPL3 glycosylation axis governs CD22 CAR T cell susceptibility in B ALL independent of antigen recognition

Multi faceted influence of immunomodulatory metabolites on CAR T cell therapy

Immune landscape characterization of relapsed refractory B cell lymphoma patients treated with CD19 CAR T cell therapy

Precision targeting of immune mediated thrombotic thrombocytopenic purpura iTTP with chimeric auto antigen receptor CAAR T cells

Microrna 142 improves IL1RAP CAR T cell activity in Acute Myeloid Leukemia

Pre infusion ADAMTS13 and VWF levels are associated with clinical outcomes of patients receiving CAR T cell therapy

IL 4 epigenetically reprograms CART19 28ζ cells to drive dysfunction

A novel CD94 targeting CAR T cell therapy for cytotoxic subtypes of T NK cell malignancies

Immune recovery and immunologic remodeling after CD19 directed chimeric antigen receptor T cell therapy in autoimmune diseases

Circadian rhythm disruption impairs CAR T cell efficacy by promoting an immunosuppressive tumor microenvironment through enhancing monocyte MDSC infiltration

Development of novel MZB1 directed HLA dependent CAR T cell and CAR enhancer therapy in MM and other B cell malignancies

Ponatinib alleviates CAR T cell exhaustion and remodels the immune microenvironment A promising combination strategy for relapsed refractory b ALL

Venetoclax enhances T cell fitness and CAR T cell manufacturing potential in chronic lymphocytic leukemia CLL

Tumor derived microRNA 125a impairs CART cell function and predicts treatment failure in B cell malignancies

Overcoming CAR T cell resistance in NPM1c and KMT2Ar AML through menin pathway inhibition